



US012064442B2

(12) **United States Patent**
Khairatkar-Joshi et al.

(10) **Patent No.:** **US 12,064,442 B2**

(45) **Date of Patent:** ***Aug. 20, 2024**

(54) **TREATMENT OF ALLERGIC RHINITIS
USING A COMBINATION OF MOMETASONE
AND OLOPATADINE**

A61P 27/14 (2006.01)

A61P 37/08 (2006.01)

(71) Applicant: **GLENMARK SPECIALTY S.A.**, La
Chaux-de-Fonds (CH)

(52) **U.S. Cl.**

CPC *A61K 31/58* (2013.01); *A61K 9/0043*
(2013.01); *A61K 31/335* (2013.01); *A61K*
31/573 (2013.01); *A61P 11/02* (2018.01);
A61P 27/14 (2018.01); *A61P 37/08* (2018.01);
A61M 11/007 (2014.02); *A61M 15/08*
(2013.01)

(72) Inventors: **Neelima Khairatkar-Joshi**, Thane (IN);
Abhay Kulkarni, Navi Mumbai (IN);
Dinesh Pradeep Wale, Maharashtra
(IN); **Vikram M. Bhosale**, Mumbai
(IN); **Piyush Agarwal**, Mumbai (IN);
Patrick Keohane, London (GB);
Sudeesh K. Tantry, Jamison, PA (US);
Chad Oh, San Francisco, CA (US)

(58) **Field of Classification Search**

CPC *A61K 31/335*; *A61K 31/573*; *A61K 31/58*;
A61K 9/0043; *A61M 11/007*; *A61M*
15/009; *A61M 15/08*; *A61P 11/02*; *A61P*
27/14; *A61P 37/08*

See application file for complete search history.

(73) Assignee: **GLENMARK SPECIALTY S.A.**,
Neuchâtel (CH)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 101 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **17/807,487**

(22) Filed: **Jun. 17, 2022**

(65) **Prior Publication Data**

US 2022/0387452 A1 Dec. 8, 2022

Related U.S. Application Data

(63) Continuation of application No. 17/003,584, filed on
Aug. 26, 2020, now Pat. No. 11,400,101, which is a
continuation of application No. 15/903,597, filed on
Feb. 23, 2018, now Pat. No. 10,758,550, which is a
continuation-in-part of application No. 15/842,063,
filed on Dec. 14, 2017, now Pat. No. 10,653,661,
which is a continuation-in-part of application No.
15/716,661, filed on Sep. 27, 2017, now abandoned,
which is a continuation-in-part of application No.
15/691,500, filed on Aug. 30, 2017, now abandoned,
which is a continuation-in-part of application No.
15/636,120, filed on Jun. 28, 2017, now Pat. No.
10,016,443, which is a continuation-in-part of
application No. 14/682,001, filed on Apr. 8, 2015,
now Pat. No. 10,548,907, which is a
continuation-in-part of application No. 14/506,122,
filed on Oct. 3, 2014, now Pat. No. 10,646,500.

(30) **Foreign Application Priority Data**

Oct. 4, 2013 (IN) 3174/MUM/2013

(51) **Int. Cl.**

A61K 31/58 (2006.01)

A61K 9/00 (2006.01)

A61K 31/335 (2006.01)

A61K 31/573 (2006.01)

A61M 11/00 (2006.01)

A61M 15/08 (2006.01)

A61P 11/02 (2006.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,871,865 A	10/1989	Lever et al.
4,923,892 A	5/1990	Lever et al.
5,062,549 A	11/1991	Smith et al.
5,837,699 A	11/1998	Sequeira et al.
6,127,353 A	10/2000	Yuen et al.
6,841,146 B2	1/2005	Haslwanter et al.
7,811,606 B2	10/2010	Chaudry
7,977,376 B2	7/2011	Singh et al.
8,399,508 B2	3/2013	Singh et al.
9,078,923 B2	7/2015	Dhuppad et al.
2004/0097474 A1	5/2004	Cagle et al.
2005/0158247 A1	7/2005	Veronesi et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	2014305 A1	1/2009
KR	101304341 B1	9/2013

(Continued)

OTHER PUBLICATIONS

Kaiser (Clinical Review, Olopatadine HCI Nasal Spray, 2008).
(Year: 2008).*

(Continued)

Primary Examiner — Umamaheswari Ramachandran

(74) *Attorney, Agent, or Firm* — Blank Rome LLP

(57) **ABSTRACT**

The present invention relates to a method of treating allergic
rhinitis in a subject (e.g., a pediatric human subject) in need
thereof comprising nasally administering to the subject an
effective amount of a fixed-dose pharmaceutical composi-
tion comprising mometasone or its salt and olopatadine or its
salt.

18 Claims, 3 Drawing Sheets